A multicentre, randomised, double-bllind, placebo- and active-controlled, phase 3 study to evaluate the efficacy and safety of TAK-875 25 mg and 50 mg compared to placebo and Sitagliptin 100mg
- Simpson, Richard (Primary Chief Investigator (PCI))
Project: Research